Drug Trial Radar · NCT07160725
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Oct 15, 2025
Primary completion
Jul 31, 2028
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
Conditions
- Solid Tumours
Interventions
BMS-986517Drug
Specified dose on specified days
PumitamigDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)Time frame: Up to approximately 2 years
- Number of Participants with Serious Adverse Events (SAE)Time frame: Up to approximately 2 years
- Number of Participants with AEs meeting protocol-defined Dose-limiting Toxicities (DLTs) criteriaTime frame: Up to Day 21
- Number of Participants with AEs Leading to DiscontinuationTime frame: Up to approximately 2 years
- Number of Participants with AEs Leading to DeathsTime frame: Up to approximately 2 years
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Local Institution - 0033
Irvine, California · Not yet recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Orange, California · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Sanford Cancer Center
Sioux Falls, South Dakota · Recruiting
START - Dallas Fort Worth
Fort Worth, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Local Institution - 0034
Guangzhou, Guangdong, China · Not yet recruiting
Copenhagen University Hospital Rigshospitalet
Copenhagen, Denmark · Recruiting
Herlev and Gentofte Hospital
Copenhagen, Capital Region, Denmark · Recruiting
Odense Universitetshospital
Odense, Region Syddanmark, Denmark · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain · Recruiting
Local Institution - 0023
Madrid, Spain · Not yet recruiting
Local Institution - 0026
Málaga, Andalusia, Spain · Not yet recruiting
Local Institution - 0022
Badalona, Barcelona [Barcelona], Spain · Not yet recruiting
Local Institution - 0024
Barcelona, Barcelona [Barcelona], Spain · Not yet recruiting
Clinica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.